Ze-zhen J. Liu
Guangdong Key Laboratory Of Clinical Molecular Medicine And Diagnostics
Guangzhou, China
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
A clinical analysis of 14 cases of prostatic stromal tumor of uncertain malignant potential
Journal: Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
Published: August 11, 2020
Offsetting Expression Profiles of Prognostic Markers in Prostate Tumor vs. Its Microenvironment.
Journal: Frontiers in oncology
Published: January 06, 2019
HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.
Journal: Pathology, research and practice
Published: January 01, 2019
TRIB1 induces macrophages to M2 phenotype by inhibiting IKB-zeta in prostate cancer.
Journal: Cellular signalling
Published: January 01, 2019
The effect of pre-operation (125)I seed activity measuring on dose accuracy
Journal: Zhonghua yi xue za zhi
Published: November 16, 2018
Functional classification of prostate cancer‑associated miRNAs through CRISPR/Cas9‑mediated gene knockout.
Journal: Molecular medicine reports
Published: May 06, 2018
Downregulation of ARID4A and ARID4B promote tumor progression and directly regulated by microRNA-30d in patient with prostate cancer.
Journal: Journal of cellular biochemistry
Published: October 22, 2017
High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Journal: International urology and nephrology
Published: December 04, 2016
Overexpression of BUB1B contributes to progression of prostate cancer and predicts poor outcome in patients with prostate cancer.
Journal: OncoTargets and therapy
Published: May 05, 2016
BCL9, a coactivator for Wnt/β-catenin transcription, is targeted by miR-30c and is associated with prostate cancer progression.
Journal: Oncology letters
Published: November 18, 2014
Showing 1-11 of 11
Last Updated: 09/26/2026